Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy (semaglutide) can affect your menstrual cycle, and many women notice changes in the first months of treatment. Periods may become irregular, heavier, lighter, or temporarily absent — particularly as body weight drops and your hormonal balance shifts. These changes are real, worth tracking, and worth discussing with your prescriber. Wegovy is a prescription-only medicine; a clinician decides whether it is suitable for you following a full assessment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The connection between semaglutide and your menstrual cycle is mostly indirect, but that does not make it less real. When body fat falls, the amount of oestrogen stored in fatty tissue falls with it. Oestrogen is central to the follicular phase of your cycle (the bit that sets up ovulation) so a meaningful drop in body fat can push the timing of your period off its usual rhythm.
There is also the question of what Wegovy does to appetite and calorie intake. In the first weeks of treatment, many people eat noticeably less, sometimes significantly less than their body is used to. Sudden caloric restriction, even temporary, can suppress the hypothalamic signalling that drives the menstrual cycle. This is the same mechanism behind cycle disruption in athletes who under-fuel. The NHS notes that weight and hormonal health are closely linked, and that weight loss medicines work best alongside dietary and lifestyle support, you can read more on the semaglutide overview page.
There may also be a direct effect of GLP-1 receptor activation on reproductive hormones, though the research here is still emerging. The honest answer is that the full picture is not yet settled. What is clear is that Wegovy's effect on periods is real for a meaningful number of women, and worth planning for rather than being surprised by.
The most common reports are: periods arriving earlier or later than usual, a heavier flow in the first one or two cycles, or a period that is lighter or shorter than normal. A smaller number of women describe a period that skips entirely for a month, particularly if weight loss has been rapid. These patterns tend to settle as weight stabilises and the body adjusts to lower oestrogen levels.
A quick habit worth building: mark the first day of each period in a calendar app or a notes app for the first three months of treatment. That single data point, tracked consistently, gives your prescriber something concrete to work with if you raise concerns at your next review, far more useful than trying to remember retrospectively whether things felt different.
If you are also experiencing significant nausea or gastrointestinal symptoms, it is worth knowing that severe vomiting and diarrhoea can affect absorption of oral contraceptive pills. The broader guide to Wegovy and periods covers this in more detail, but the short version is: use a barrier method as a back-up if you have been unwell for more than 24 hours while taking the pill.
This is the part of the conversation that catches many women off guard. Excess weight is associated with ovulatory dysfunction, polycystic ovary syndrome (PCOS) being the clearest example, where higher insulin levels and androgen excess disrupt regular ovulation. When weight falls and insulin sensitivity improves, ovulation can return or become more regular, sometimes quickly.
That is a positive development for women trying to conceive. But it also means that women who assumed irregular cycles meant low fertility risk can become unexpectedly pregnant during treatment. Wegovy is not recommended during pregnancy. The guidance on missed periods during Wegovy treatment addresses this directly: if a period is late and you are sexually active, a pregnancy test is a sensible first step before assuming the absence is treatment-related.
The full Wegovy treatment page sets out the safety profile in more detail. If you are planning a pregnancy in the near future, that is exactly the kind of conversation to have during your consultation, timing, contraception during treatment, and when to stop before trying to conceive all require a prescriber's input rather than a general answer.
Most cycle changes on Wegovy are self-limiting. But some warrant a conversation sooner rather than later. Contact a clinician if you experience very heavy bleeding (soaking through more than one pad or tampon per hour for two or more consecutive hours), cycles that remain absent for three months or more, or any symptoms that feel new and unexplained, particularly if you also have pelvic pain.
If you are already taking Wegovy privately and want to discuss how it is affecting your cycle, our aftercare team is available seven days a week. If you are weighing up whether Wegovy is right for you given your menstrual health history, our prescribers review each consultation individually, you can find out more about the clinical team on the clinical lead's profile page. Some women also find it helpful to read about what period changes to expect at different stages of treatment before starting.
If you have questions about managing other medicines alongside Wegovy (including anything that might interact with your cycle or contraception) the FAQs page is a practical starting point. And if you decide you are ready to move forward, you can start your free consultation with our prescribers today.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.